Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Author(s): Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
Issue: Mar/Apr 2012 - Volume 16, Number 2
View All Articles in Issue
Page(s): 164-166
Download in electronic PDF format for $75
Abstract: Omeprazole is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome. Omeprazole is marketed by AstraZeneca under a number of names, most notably Prilosec and Losec, as well as being available from a number of generic manufacturers. Omeprazole is available in both tablet and capsule form, with varying strengths of each. The need for other administration options for those patients who cannot take tablets or capsules has led compounding pharmacies to seek other alternatives. One possible alternative is the use of a suspending agent to create an oral solution or suspension. In the past, this has been accomplished using a sodium bicarbonate solution as the vehicle. However, sodium bicarbonate/omeprazole combination imparts a bitter and unpleasant taste. SyrSpend SF Alka (reconstituted) is a vehicle for making a suspension which has a pleasant taste, thus increasing palpability and compliance. The objective of this study was to determine the stability of omeprazole in SyrSpend SF Alka (for reconstitution). The studied sample was compounded into a 2-mg/mL suspension and stored in a low-actinic plastic prescription bottle at temperatures between 2oC and 8oC. Six samples were assayed at each time point out to 92 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced degradation studies. The shelf life of this product is at least 92 days, based on data collected when refrigerated and protected from light.
Related Keywords:
Paul A. Whaley, BS, Mark A. Voudrie II, MS, PMP, Bridget Sorensen, CAPM, omeprazole, peptic ulcer disease, gastroesophageal reflux disease, GERD, dyspepsia, suspension, stability
Related Categories:
EXCIPIENTS, GASTROENTEROLOGY, PACKAGING, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
|
Mar/Apr 2012
Pg. 164-166
|
The Treatment of Canine Atopic Disease
Davidson Gigi S
|
May/Jun 2002
Pg. 210-215
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Corsini Lindsay, Williams LaVonn A
|
Mar/Apr 2011
Pg. 124-128
|
Treating Canine Hepatic Disease
Davidson Gigi S
|
May/Jun 2003
Pg. 188-191
|
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
|
Mar/Apr 2020
Pg. 140-147
|
Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
|
May/Jun 2023
Pg. 250-255
|
Omeprazole 2 mg/mL in SyrSpend SF Alka (Reconstituted)
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 409
|
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 513-515
|
Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
|
Nov/Dec 2019
Pg. 504-510
|
Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 58
|
Stability of Gabapentin in SyrSpend SF
Sorenson Bridget, Voudrie Mark A II, Gehrig Dan
|
Jul/Aug 2012
Pg. 347-349
|
Stability of Ursodiol in SyrSpend SF Cherry Flavored
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 510-512
|
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 344-346
|
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A, Alexander Bridget, Allen D Brett
|
May/Jun 2011
Pg. 255-258
|
Omeprazole 2-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 389
|
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul
|
Sep/Oct 2015
Pg. 420-427
|
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
|
Nov/Dec 2017
Pg. 500-512
|
Stability of Vancomycin in SyrSpend SF
Whaley Paul A, Voudrie Mark A II
|
Mar/Apr 2012
Pg. 167-169
|
Stability of Captopril in SyrSPend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 336-338
|
Return to Top |